← Back to patent-cliff list
CAS 288-13-1
1,2-Diazole1H-pyrazole
Codes: (XXIX)1024528-1-c, CRIT-021, PALOV-010, TASE-025, ITACI-018
Application context (from source-drug indications)
Non-small cell lung cancerPralsetinibThyroid cancerPralsetinibMedullary thyroid cancerPralsetinibPrimary cutaneous anaplastic large cell lymphomaCrizotinibAnaplastic large cell lymphomaCrizotinibNon-small cell lung cancerCrizotinibSchwannomaCrizotinibNeurofibromatosis type IICrizotinibMultiple myelomaCrizotinib进行性肌肉骨化症PalovaroteneHepatic function declinePalovarotene异位骨化Palovarotene遗传性多发性外生骨疣PalovaroteneDry eye syndromePalovaroteneEmphysemaPalovaroteneBreast cancerTaselisibBladder cancerTaselisibMultiple myelomaTaselisibLung cancerTaselisibLiver cancerTaselisibCervical cancerTaselisibDiffuse large B-cell lymphomaItacitinibMyeloproliferative neoplasmItacitinibAcute lymphoblastic leukaemiaItacitinibAcute myeloid leukaemiaItacitinibChronic myelomonocytic leukaemiaItacitinib骨髓增生异常-骨髓增生性疾病Itacitinib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Pralsetinib | Tier C — Watch / trade | 2031 |
| Crizotinib | Tier C — Watch / trade | - |
| Palovarotene | Tier C — Watch / trade | - |
| Taselisib | Tier C — Watch / trade | - |
| Itacitinib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
1-[6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethan-1-one→4-Fluoro-1H-pyrazole→2,2,3,3-Tetrafluoropropan-1-ol→4-(2,2,3,3-Tetrafluoropropyl)morpholine→4-Methyl-4-(2,2,3,3-tetrafluoropropyl)morpholin-4-ium mesylate→1,2-Diazole→4-Methyl-4-[(1Z)-2,3,3-trifluoroprop-1-en-1-yl]morpholin-4-ium methanesulfonate→(2Z)-2-Fluoro-3-(morpholin-4-yl)prop-2-enal→Hydrazine dihydrochloride→4-Fluoro-1H-pyrazole hydrogen chloride→5-Bromo-2-chloropyridine→Acetic acid acetic anhydride→1-(6-Chloropyridin-3-yl)ethanone
2,5-dimethylhexane-2,5-diol→2,5-dichloro-2,5-dimethylhexane→1-bromo-2-methylbenzene→6-bromo-1,1,4,4,7-pentamethyl-1,2,3,4-tetrahydronaphthalene→3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalene-2-carbonitrile→3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalene-2-carbaldehyde→methyl 4-((dimethoxyphosphoryl)methyl)benzoate→(E)-methyl 4-(2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoate→(E)-methyl 4-(2-(3-(bromomethyl)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoate→1H-pyrazole→(E)-methyl 4-(2-(3-((1H-pyrazol-1-yl)methyl)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoate
9-bromo-2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine→4-bromo-2-fluorobenzonitrile→4-bromo-2-fluoro-N-hydroxybenzimidamide→ethyl propiolate→ethyl 3-((4-bromo-2-fluorobenzimidamido)oxy)acrylate→ethyl 2-(4-bromo-2-fluorophenyl)-1H-imidazole-4-carboxylate→1,3-dioxolan-2-one→ethyl 2-(4-bromo-2-fluorophenyl)-1-(2-hydroxyethyl)-1H-imidazole-4-carboxylate→9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxylic acid→9-bromo-N-(1-iminoethyl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide→ethyl 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate→ethyl 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoate→2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoic acid→ethyl 2-bromo-2-methylpropanoate→1H-pyrazole→ethyl 2-methyl-2-(1H-pyrazol-1-yl)propanoate→2,5-dibromo-4,4-dimethylcyclopentane-1,3-dione→ethyl 2-(4-bromo-1H-pyrazol-1-yl)-2-methylpropanoate→4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)
diphenylmethanamine→2-(chloromethyl)oxirane→1-benzhydrylazetidin-3-ol hydrochloride→tert-butyl 3-hydroxyazetidine-1-carboxylate→tert-butyl 3-oxoazetidine-1-carboxylate→diethyl (cyanomethyl)phosphonate→tert-butyl 3-(cyanomethylene)azetidine-1-carboxylate→4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)-1H-pyrazole→tert-butyl 3-(cyanomethyl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate→4-chloro-7H-pyrrolo[2,3-d]pyrimidine→tert-butyl 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-(cyanomethyl)azetidine-1-carboxylate→2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile dihydrochloride→1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-one→1,4-dioxa-8-azaspiro[4.5]decane hydrochloride→1,4-dioxa-8-azaspiro[4.5]decane→3-fluoro-2-(trifluoromethyl)isonicotinic acid→(3-fluoro-2-(trifluoromethyl)pyridin-4-yl)(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)methanone→1H-pyrazole→4-iodo-1H-pyrazole→4-iodo-1-(trimethylsilyl)-1H-pyrazole→2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane→2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile→2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | tert-Butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H- pyrazol-1-yl]piperidine-1-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | [5-Bromo-3-[(1R)-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin -2- yl]amine Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2-amino-5-bromopyridin-3-ol Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.